TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Priovi), which was designed to introduce relevant schema therapy techniques to Persons with Borderline Personality Disorder (BPD). Therefore, 200 people with BPD will be recruited and randomized to two groups: (1) a control group, in which they may engage with any BPD treatment (Care-as-Usual, CAU) and receive access to Priovi after a delay of 12 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Priovi and may also use CAU. The primary outcome measure is the score of the Borderline Personality Disorder Severity Index (BPDSI), collected at three, six and 12 month post-baseline.


Options:
A: Inclusion Criteria:

* Diagnosis of AD
* Diagnosis of BPD

Exclusion Criteria:

* Serious or unstable medical condition
* Opiate dependence
* Major Axis I disorder (bipolar disorder, schizophrenia)
* Taking mood stabilizers and antipsychotic medications
* LFT abnormalities that do not exceed 3 times normal values
B: Inclusion Criteria:

* Psychiatric diagnosis of BPD
* BPDSI score of 15 or higher
* Informed consent
* German language proficiency
* Willingness to participate in diagnostic and follow-up assessments as well as to see a -
* Psychiatrist for validation of diagnosis
* 18 years or older

Exclusion Criteria:

* Psychotic disorder
* Primary psychiatric diagnosis of an addictive disorder
* Schizotypal personality disorder
C: Inclusion Criteria:

* DSM-IV Borderline Personality Disorder;
* between 18 and 65 yrs of age

Exclusion Criteria:

* DSM-IV psychotic disorders,
* mental retardation,
* substance abuse in the forefront
D: Inclusion Criteria: Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine).

-

Exclusion Criteria: Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.)

-

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Priovi), which was designed to introduce relevant schema therapy techniques to Persons with Borderline Personality Disorder (BPD). Therefore, 200 people with BPD will be recruited and randomized to two groups: (1) a control group, in which they may engage with any BPD treatment (Care-as-Usual, CAU) and receive access to Priovi after a delay of 12 months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives 12-month access to Priovi and may also use CAU. The primary outcome measure is the score of the Borderline Personality Disorder Severity Index (BPDSI), collected at three, six and 12 month post-baseline.


Options:
A: Inclusion Criteria:

* All students in term 3 of their medical and psychology study at the University of Oslo in the autumn of 2009, and spring of 2010.
* All students in term 3 of their medical and psychology study at the University of Tromso in the autumn of 2010, and autumn of 2011.
B: Inclusion Criteria:

* Women
* Age 18 - 45
* Borderline Personality Disorder, by DSM-V

Exclusion Criteria:

* Current Acute Depressive Episode
* Current Psychotic Episode
* Less Than 12 school years
* Non Compliance with therapy
* Dual diagnosis
C: Inclusion Criteria:

* Psychiatric diagnosis of BPD
* BPDSI score of 15 or higher
* Informed consent
* German language proficiency
* Willingness to participate in diagnostic and follow-up assessments as well as to see a -
* Psychiatrist for validation of diagnosis
* 18 years or older

Exclusion Criteria:

* Psychotic disorder
* Primary psychiatric diagnosis of an addictive disorder
* Schizotypal personality disorder
D: Inclusion Criteria:

1. patients meeting DSM-IV criteria for borderline personality disorder,
2. 18-60 years of age
3. have had at least two episodes of suicidal or non-suicidal self-injurious episodes in the past 5 years
4. at least one of which is in the 3 months preceding enrollment
5. agreement to participate in evaluation of the program

Exclusion Criteria:

1. having a DSM-IV diagnosis of a psychotic disorder, bipolar I disorder, delirium, dementia, mental retardation, or a diagnosis of substance dependence in the preceding 30 days
2. living outside of Taipei area
3. having any serious medical condition likely to require hospitalization within the next year (e.g. cancer)
4. having plans to leave the Taipei area in the next 1 year

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Can a Single-unit Blood Transfusion Protocol in Obstetrics Reduce Total Number of Units Transfused? A Randomized, Controlled Trial
Brief Summary: There is a paucity of data on management of non-acute postpartum anemia. Although blood transfusions were historically initiated with 2 units, the most recent recommendation from the American Association of Blood Banks is to begin with 1 unit. As no randomized controlled trials have been performed in obstetrics, the investigators propose a randomized, controlled trial in non-acute postpartum anemia comparing single- versus multiple-unit transfusion by total numbers of units transfused and maternal morbidity.


Options:
A: Inclusion Criteria:

* Women over 18
* Willing and stable to give consent
* \> 6 hours postpartum from any mode of delivery
* Determined by their physician to require blood transfusion either by:

  * Hb \<7g/dL OR
  * \>7g/dL with any sign or symptom of anemia such as fatigue, dizziness, tachycardia, or hypotension
* Agreed to accept blood transfusion
* No contraindications to blood transfusion

Exclusion Criteria:

* hemoglobinopathies
* patients with an ejection fraction \<35%
* Hb \<5 g/dL
* HR \> 130 bpm, BP \< 80/40
B: Inclusion Criteria:

* All elective primary and redo adult cardiac surgical patients for coronary artery bypass grafting, valve procedure or combined procedures
* Adults patients
* Written informed consent

Exclusion Criteria:

* Age less than 18 years
* Transplant procedures
* Emergency procedures
* Aortic repairs
* Congenital procedures
* Previous anemia (hemoglobin lower than 10 g/dL)
* Previous thrombocytopenia (platelet number lower than 100.000/mm3)
* Previous known coagulopathy
* Pregnancy
* Those unable to receive blood transfusion
* Patients who refused participation in the study
C: Inclusion Criteria:

* Patient requiring surgery for an isolated hip fracture of less than 48 hours

Exclusion Criteria:

* Contraindication to tranexamic acid
* Contraindication to fondaparinux
* Contraindication to general anesthesia associated with a femoral nerve block
* pregnancy
D: Inclusion Criteria:

* Care Score of 3/4 or age \>/= 80
* Signed informed consent

Exclusion Criteria:

* Patients who refuse participation
* Unable to or refuse blood products
* Involved in an autologous pre-donation program

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Do Probiotics Modulate the Intestinal Microbiome of Extremely Preterm Infants?
Brief Summary: The gut microbiome plays a significant role in balancing the inflammatory system in the immature gut. A breakdown in this balance with altered colonization of the microbiota in very low birth weight (VLBW) preterm infants is associated with increased feeding intolerance, necrotizing enterocolitis (NEC) and sepsis. Probiotics are proposed to normalize microbial populations and decrease intestinal disease in preterm infants. There is limited data linking clinical outcomes with the biology of probiotics. We aim to study the colonization of the GI tract with probiotic species contained in a specific probiotic blend - Florababy - in VLBW preterm infants.

Stool microbiome will be analyzed at 4 time points in 2 groups (one given Florababy and the other no) of infants less than 1000 grams birth weight and \< 29 weeks gestation. A comparison of stool microbiome analysis and the incidence of feeding intolerance and time to reach full feeds in the two groups will be made.


Options:
A: Inclusion Criteria:

* Pregnant women from families with at least one family member having an allergic disease

Exclusion Criteria:

* Women presenting severe immunological or other chronic diseases (rheumatoid arthritis, diabetes, inflammatory bowel disease, thyroid diseases, malignancies etc.)
* Women who cannot be expected to comply with treatment
* Women currently participating or having participated in other clinical trial during the last 2 months prior to the beginning of the intervention.
B: Inclusion Criteria:

* Preterm infants born between week 28 + 0 days and week 30 + 6 days of gestation.
* Written informed consent signed by the parent or legal guardian.
* Tolerate enteral feeding, at least 10mL / kg / day.
* Postnatal age ≤ 5 days

Exclusion Criteria:

* Child with malformations
* With short bowel syndrome or any surgery in the gastrointestinal tract
* With defect in the intestinal epithelial barrier
C: Inclusion Criteria:

1. newborns (\< 2 weeks of life)
2. 32 Weeks of Gestation,
3. weight \< 1500g,
4. Enteral nutrition begun,
5. Clinical stability,
6. Signed consent form from both parents.

Exclusion Criteria:

1. newborns (\>= 2 weeks of life),
2. weight \>= 1500g,
3. pathology avoiding the start of the enteral nutrition,
4. other pathologies of those due to premature and its complications,
5. No signed consent form.
D: Inclusion Criteria:

* Infants born less than 29 weeks gestation and \<1000 g birth weight admitted to the Neonatal Intensive Care Unit (NICU) at Foothills Medical Centre in Calgary.

Exclusion Criteria:

* Infants with major congenital anomalies, hypoxic-ischemic injury, NEC or bowel perforation before 72 hours of life.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Gluconate Cloth and Chlorhexidine Gluconate Vaginal Scrub Reduces Infectious Morbidity in Patients Undergoing Cesarean Section After Labor
Brief Summary: Surgical site infections (SSI) are the second most common cause of nosocomial infections accounting for 15% of all nosocomial infections among hospitalized patients and 38% of nosocomial infections in surgical patients. In obstetric patients, infectious morbidity (i.e. SSI, endometritis) occurs in 5-10% of cesarean sections, which is 5-fold higher than vaginal deliveries. Additionally, infectious morbidity is thought to be highest in those patients who have cesarean sections after undergoing labor.

Chlorhexidine, a chemical antiseptic effective on gram positive and gram negative bacteria, reduces skin microflora/colonization but it is not clear if it decreases the risk of SSI.

Historically, chlorhexidine has been studied and used in orthopedic and cardiac implant surgeries. Research on the use of chlorhexidine for SSI prevention in cesarean sections is limited. This study intends to evaluate the effectiveness of use of both chlorhexidine gluconate (CHG) wipe and vaginal scrub in reducing SSI in patients undergoing cesarean section that have previously been laboring. Patients will be randomized to one of two groups: wash with both a pre-operative CHG cloth prior to surgery and chlorhexidine gluconate vaginal scrub in addition to standard preoperative scrub as compared to standard preoperative scrub alone.


Options:
A: Inclusion Criteria:

* Woman undergoing cesarean delivery
* At least 18 years of age

Exclusion Criteria:

* Allergy to iodine containing solutions
* Planned cesarean hysterectomy
* Prisoner
B: Inclusion Criteria:

* Females aged 18-50 years
* The study will be offered to women at \> 24 weeks gestation who are undergoing nonemergent cesarean delivery with ruptured amniotic membranes.
* All patients undergoing cesarean delivery with ruptured amniotic membranes.

Exclusion Criteria:

* Minors
* Emergent cesarean delivery.
* No ruptured membranes.
* Allergy to chlorhexidine or povidone-iodine.
C: Inclusion Criteria:

* Women at \> 24 weeks gestation who are admitted in labor or admitted for induction of labor at Mount Sinai Hospital

Exclusion Criteria:

* Allergy to chlorhexidine
* Unplanned or emergency cesarean section
* Women at \<24 weeks gestation
* Estimated fetal weight \<500 grams
* Fetal face presentation regardless of gestational age.
D: Intervention Group (vaginal preparation)

Inclusion Criteria:

* Pregnant women admitted for cesarean delivery
* Gestational age greater than or equal to 34 weeks

Exclusion Criteria:

* Rupture of membranes or active labor
* Chorioamnionitis (prior to enrollment)
* Recent (within 4 weeks) antibiotic exposure
* Maternal HIV infection or immunocompromised state
* Known allergy to shellfish, iodine, or chlorhexidine

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: mDOT: A Pilot Study of Video Directly Observed Therapy for Immunosuppressant Adherence in Adult Kidney Transplant Recipients
Brief Summary: The investigators are interested in whether or not the use of a mobile health (mHealth) application increases the rate of immunosuppression medication adherence among adult kidney transplant recipients. The investigators aim to test this by randomly assigning transplant recipients to the intervention (use of an mHealth app to manage and track their immunosuppression regimen) or control arm (standard of care) upon discharge from their initial transplant hospitalization, and tracking medication adherence over time. The study population will be approximately 50 adult kidney transplant recipients at the Johns Hopkins Hospital.


Options:
A: Subject is eligible for the study if the following apply:

* Receiving a kidney transplant from a deceased or living donor in Karolinska University Hospital
* Capable of understanding the purpose of the study, fully informed and having written informed consent (signed Informed Consent has been obtained)

No study-specific exclusion criteria
B: Inclusion Criteria:

* Adults (≥22 years)
* Receive a kidney transplant at the Johns Hopkins Hospital

Exclusion Criteria:

* Non-English speaking participants
C: Inclusion Criteria:

1. Male and female subjects (≥ 18 years old) who are liver transplant recipients.
2. Discharged home within 45 days of liver transplant.
3. Able and willing to provide informed consent.

Exclusion Criteria:

1. Post-transplant admission and care provided by University of Cincinnati Medical Center or rehab facility \> 45 days after liver transplant.
2. Unable to have 4G wireless connectivity or wifi in their home.
3. Patient has any form of psychiatric disorder or a condition that, in the opinion of the investigator, may hinder communication with the investigator.
4. Inability to cooperate or communicate with the investigator.
D: Inclusion Criteria:

* Patient is an adult (18 years of age or older).
* Patient is a recipient of a deceased or living donor kidney transplant.
* Patient is able to comply with study procedures for the entire length of the study.
* Patient has been informed about the study survey and has signed an informed consent form.

Exclusion Criteria:

* Patient is unable or unwilling to complete study patient reported outcome questionnaires.
* Patient is currently receiving azathioprine
* Patient is currently receiving an mTOR inhibitor (sirolimus, everolimus)
* Patient is currently receiving an belatacept
* Patient has received investigational immunosuppression 1 month prior to transplant or post-transplant
* Patient is in a setting where a professional care taker is responsible for dispensing subject's medication.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomised Controlled Comparison of Effectiveness of Facemask Preoxygenation and Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in Bariatric Patients Undergoing General Anaesthesia
Brief Summary: The purpose of the study is to compare effectiveness of different methods of achieving pre-oxygenation in bariatric patients. The investigators intend to compare facemask pre-oxygenation with a high-flow humidified nasal oxygen.

The primary outcome measure of interest is time to desaturation to 92% or 18 minutes of apnoea.


Options:
A: Inclusion Criteria:

1. Adult, \>18 years old
2. ENT-surgery where apnea is of benefit for the surgeon (eg. intraoral or laryngeal surgery) and the anesthesia time is \<40 mins.
3. Capable of understanding the study information and sign the written consent.

Exclusion Criteria:

1. ASA\>2
2. NYHA \>2
3. BMI \>30
4. Pregnancy
5. Manifest cardiac failure or coronary disease
6. Neuromuscular disease
B: Inclusion Criteria:

* Obese patient with BMI \> 35kg/m2
* Age between 18 and 80 years
* Requiring a crash induction sequence for oro-tracheal intubation.

Exclusion Criteria:

* Pulse oxymetry \< 90% in ambient air
* Haemodynamic instability
* Burned patient
* Indication of intubation vigil in spontaneous ventilation
* Patients with a documented Cormack IV exposition before inclusion
* Protected adult
* Pregnancy
* Lack of consent
* Patient already enrolled in an other randomized study looking forward improving preoxygenation quality.
* Lack of French social protection
C: Inclusion Criteria:

* Age more than18 years old
* ASA status I-III
* Elective surgery performed under general anesthesia requiring endotracheal intubation
* BMI more than 40 kg/m2

Exclusion Criteria:

* Chronic respiratory disease
* SpO2 \<98% after supplementing oxygen
* Previous or anticipated difficult intubation
* Uncontrolled hypertension
* Ischemic heart disease
* Congestive heart failure
* Increased intracranial pressure
* Uncontrolled GERD
* Known allergy or contraindication to anesthesia drugs
* Nasal blockade contraindicating the use of HFNC
D: Inclusion Criteria:

* Able to provide informed consent.
* Undergoing general anaesthesia .
* Between the ages of 18 and 80 years.
* Body mass index (BMI) greater than 40 Kgm-2.

Exclusion Criteria:

* Unable to give informed consent.
* Significant cardiac history which is defined as current angina, myocardial infarction \<12 months before the date of the procedure.
* Significant peripheral vascular disease defined as claudication on minimal exertion or Ankle-Brachial index of \<0.7, a stroke or a transient ischaemic attack \<12 months before the procedure.
* Presence of significant heart-valve disease or congestive heart failure.
* Significant lower respiratory disease including brittle asthma; chronic obstructive pulmonary disease (GOLD stages 3 or 4).
* Strong predictors of both difficult intubation and difficult facemask ventilation on anaesthetic airway assessment.
* Patient with American Society of Anesthesiologists (ASA) grade of 4 for any reason.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy
Brief Summary: Inguinal lymph node dissection (ILND) is indicated following metastatic malignant melanoma, and is associated with a high-complication rate, of which many begin with the formation of seroma and ends in complicated wound healing, reoperation, multiple outpatient visits and re-hospitalization. Prevention of seroma may therefore lead to a reduction of many of the preceding complications and improve patient quality-of-life. The aim of this study is to evaluate the efficacy and oncological safety of prophylactic negative pressure wound therapy following ILND in melanoma patients.


Options:
A: Inclusion Criteria:

* patients presenting to wound center undergoing wound treatment with expected closure of wounds including: Midfoot amputations, below knee amputations, knee disarticulations, above knee amputations, and trunk wounds
* wounds must be closed primarily without the use of grafts

Exclusion Criteria:

* any patient \<18 years old
* any patient whose wound is unable to be closed primarily
B: Inclusion Criteria:

* Written informed consent
* Coronary heart disease patients to transplant more than 2 vascular bridge
* The thigh groin following from the saphenous vein

Exclusion Criteria:

* Subjects does not agree to participate in clinical trials
* Subjects had a injury, operation history of Thigh
* Subjects having ever received chemotherapy before the surgery
* Subjects with known hypersensitivity to components of the surgical sticky membrane
C: Inclusion Criteria:

* All malignant melanoma patients who are candidates for ILND and 18 years of age or older

Exclusion Criteria:

* Patients suspected of having tumor residuals after ILND, previous groin irradiation or patients suffering from dementia or any psychiatric disorder making them incapable of informed consent or adherence to follow up, along with patients who are unable to communicate in Danish or English will not be included in the study.
D: Inclusion Criteria:

* Pregnant women with BMI \> 40 undergoing a cesarean delivery at Parkland Health and Hospital System.

Exclusion Criteria:

* Any patient not meeting inclusion criteria will be deemed ineligible.
* All HIV positive patients will be excluded due to the increased risk of infectious complications in these patients.
* Although patients on anticoagulants can use NPWT, they will be excluded as there may be an increased risk of bleeding in these patients.
* according to the wound therapy manufacturer's instructions patients with:

  * fragile skin
  * allergy to silver or acrylic adhesives
  * a malignancy in the wound bed or margins of the wound bed
  * non-enteric and unexplored fistulas
  * necrotic tissue with eschar present
  * exposed arteries, veins, nerves or organs, anastomotic sites, or surgical suction are not candidates for usage of the device.

Answer: C